Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandro Matosevic

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Trends in Pharmacological Sciences|September 28, 2023
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunitiesShambhavi Borde, Sandro Matosevic
Journal of Molecular Medicine (Berlin, Germany)|August 3, 2018
Adenosinergic signaling as a target for natural killer cell immunotherapyJiao Wang, Sandro Matosevic
Medicinal Research Reviews|March 10, 2026
Immunosuppressive Tumor Microenvironment and Therapeutic Landscape of Diffuse Intrinsic Pontine GliomaShuyi Zhou, Sandro Matosevic
Journal of Clinical Medicine|September 25, 2019
<i>NT5E</i>/CD73 as Correlative Factor of Patient Survival and Natural Killer Cell Infiltration in GlioblastomaJiao Wang, Sandro Matosevic
Cancer Metastasis Reviews|January 24, 2025
The diversity of natural killer cell functional and phenotypic states in cancerKumar Rishabh, Sandro Matosevic
Molecular Therapy Oncolytics|November 24, 2022
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapyXinyu Wu, Sandro Matosevic
Trends in Pharmacological Sciences|March 28, 2025
Afamitresgene autoleucel: first cell therapy for synovial sarcomaSoumyajit Das, Sandro Matosevic
Journal of Hematology & Oncology|June 14, 2020
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastomaKyle B Lupo, Sandro Matosevic
Nature Chemistry|October 25, 2013
Layer-by-layer cell membrane assemblySandro Matosevic, Brian M Paegel
Cancers|June 6, 2019
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer ImmunotherapyKyle B Lupo, Sandro Matosevic
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Trends in Pharmacological Sciences|September 28, 2023
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunitiesShambhavi Borde, Sandro Matosevic
Journal of Molecular Medicine (Berlin, Germany)|August 3, 2018
Adenosinergic signaling as a target for natural killer cell immunotherapyJiao Wang, Sandro Matosevic
Medicinal Research Reviews|March 10, 2026
Immunosuppressive Tumor Microenvironment and Therapeutic Landscape of Diffuse Intrinsic Pontine GliomaShuyi Zhou, Sandro Matosevic
Journal of Clinical Medicine|September 25, 2019
<i>NT5E</i>/CD73 as Correlative Factor of Patient Survival and Natural Killer Cell Infiltration in GlioblastomaJiao Wang, Sandro Matosevic
Cancer Metastasis Reviews|January 24, 2025
The diversity of natural killer cell functional and phenotypic states in cancerKumar Rishabh, Sandro Matosevic
Molecular Therapy Oncolytics|November 24, 2022
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapyXinyu Wu, Sandro Matosevic
Trends in Pharmacological Sciences|March 28, 2025
Afamitresgene autoleucel: first cell therapy for synovial sarcomaSoumyajit Das, Sandro Matosevic
Journal of Hematology & Oncology|June 14, 2020
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastomaKyle B Lupo, Sandro Matosevic
Nature Chemistry|October 25, 2013
Layer-by-layer cell membrane assemblySandro Matosevic, Brian M Paegel
Cancers|June 6, 2019
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer ImmunotherapyKyle B Lupo, Sandro Matosevic
Pageof 5